clinical trial · NCT05878717
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
GlaxoSmithKline·phase3·recruiting·n = 300
Systemic Sclerosis Associated Interstitial Lung DiseaseScleroderma, SystemicBelimumabPlacebo
brief summary
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
started
Sep 13, 2023
primary completion
May 17, 2029
completion
Jul 12, 2029
last updated
Jan 12, 2026
official title
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol